BIO FPX 1000 Assessment 6 Patient Case Study Profiles – Cancer Causes

Student Name

Capella University

BIO FPX 1000 Human Biology

Prof. Name

Date

BIO FPX 1000 Assessment 6 Patient Case Study Profiles – Cancer Causes

Breast cancer risk varies from person to person and is influenced by factors such as age, family history, reproductive history, hormone exposure, alcohol use, body weight, and inherited genetic mutations. In these four patient profiles Mary, Paula, June, and Nora several factors increase breast cancer risk, particularly family history and possible hereditary cancer syndromes. Risk assessment should be individualized, and recommendations may include appropriate screening, genetic counseling or testing, healthy lifestyle changes, and management of other medical conditions. Importantly, hormone replacement therapy should not be recommended as a way to reduce breast cancer risk without careful evaluation by a qualified healthcare professional.

Mary: Breast Cancer Risk Factors

Mary is a 64-year-old woman who had her first child at age 20 and experienced menopause at 58. After menopause, she used estrogen replacement therapy for approximately six years and subsequently gained weight. Her mother developed breast cancer at age 37, and Mary experienced menarche at age 13.

Mary’s most important breast cancer risk factor is her strong family history. Having a first-degree relative, such as a mother or sister, with breast cancer can increase an individual’s risk, particularly when the relative was diagnosed at a young age. Early-onset breast cancer in a close relative may also raise concern about an inherited genetic predisposition.

Her history of postmenopausal hormone therapy and weight gain may also be relevant. Research has identified associations between certain forms of menopausal hormone therapy, body weight, and breast cancer risk, although the degree of risk depends on factors such as the type of hormone therapy, duration of use, and individual characteristics.

Mary’s Breast Cancer Risk Assessment

A breast cancer risk calculator may provide an estimate of an individual’s short-term and lifetime risk, but the result depends on the specific model and the information entered. Risk estimates should therefore be interpreted in the context of Mary’s personal and family history rather than viewed as a definitive prediction.

Because Mary’s mother developed breast cancer at a young age, genetic counseling may be appropriate. A healthcare professional can determine whether Mary meets criteria for genetic testing for hereditary breast cancer genes such as BRCA1 and BRCA2.

Recommendations for Mary

Mary should discuss her family history and previous hormone therapy with her healthcare provider. Depending on her calculated risk and family history, her provider may recommend routine mammography and, if she is considered high risk, additional imaging such as breast MRI.

Healthy lifestyle measures can also help reduce modifiable breast cancer risk. These may include maintaining a healthy body weight, participating in regular physical activity, limiting alcohol consumption, and following a balanced diet.

Estrogen therapy should not be continued specifically to prevent breast cancer. Decisions about menopausal hormone therapy should consider its indications, benefits, risks, duration, and the individual’s personal and family history.

Paula: Breast Cancer and Hereditary Cancer Risk

Paula is 71 and is being treated for bladder cancer that has spread to her ovaries and lymphatic system. Her sister was treated for breast cancer three years ago, while her mother died from lung cancer. Paula also reports cancer diagnoses in two paternal uncles and her maternal grandmother.

This pattern of cancer across several relatives raises concern about a possible hereditary cancer syndrome. The concern becomes greater because Paula’s sister reportedly carries a BRCA1 mutation. BRCA1 and BRCA2 pathogenic variants are associated with increased risks of breast and ovarian cancers, among other cancers.

Paula’s Breast Cancer Risk Assessment

A family history involving multiple relatives with cancer does not automatically establish that Paula has a hereditary cancer mutation. However, a known BRCA1 mutation in a close relative provides a strong reason to discuss genetic counseling and testing.

If Paula has not been tested, a genetic counselor can review her family history and determine the appropriate genetic test. If she carries the familial BRCA1 mutation, her healthcare team can develop a surveillance and risk-management plan based on her age, current cancer diagnosis, treatment status, and overall health.

Recommendations for Paula

Paula’s immediate cancer care should be coordinated by her oncology team. Because she already has advanced bladder cancer, treatment decisions should be based on the cancer’s pathology, stage, molecular characteristics, previous treatments, and overall health rather than family history alone.

Chemotherapy may be part of bladder cancer treatment for some patients, but it is not appropriate to recommend chemotherapy solely because a patient has a family history of breast cancer. Her oncology team should determine whether chemotherapy, immunotherapy, targeted therapy, surgery, radiation, or another treatment is appropriate.

Genetic counseling is particularly relevant because of her sister’s reported BRCA1 mutation. Paula should also discuss appropriate breast surveillance with her healthcare providers.

June: Breast Cancer Risk Factors

June is 58 and receives regular mammograms. Her family history includes an aunt with breast cancer and a mother who had a brain tumor. She also has high blood pressure, elevated cholesterol, and fragile bones.

June’s family history may contribute to her breast cancer risk, although an aunt is a second-degree relative and generally provides less risk information than a first-degree relative such as a mother or sister with breast cancer. The type of her mother’s brain tumor is also important because not all brain tumors are associated with hereditary breast cancer syndromes.

Her previous use of oral contraceptives may be relevant because research has found a small association between current or recent hormonal contraceptive use and breast cancer risk. However, the relationship is complex, and contraceptive history should be considered alongside other risk factors.

Recommendations for June

June should continue breast cancer screening according to recommendations appropriate for her age and individual risk. For women at average risk, mammography is generally performed at regular intervals rather than every few weeks. Women with substantially elevated hereditary or lifetime risk may require a different surveillance strategy.

Because June has hypertension and elevated cholesterol, cardiovascular risk management is also important. A healthy dietary pattern, such as the DASH eating plan, can support blood pressure and cardiovascular health.

Her fragile bones also warrant appropriate evaluation for osteoporosis. Adequate calcium and vitamin D intake, weight-bearing physical activity, and osteoporosis screening or treatment when indicated can help protect bone health.

Nora: Breast Cancer Risk Factors

Nora is 51 and has not yet reached menopause. Her family history includes both breast cancer and colon cancer. Based on the risk estimates provided in the case, her projected breast cancer risk is higher than the average risk for women in the comparable population.

A family history involving breast cancer and colon cancer can be important when assessing hereditary cancer risk. However, the significance depends on which relatives were affected, their ages at diagnosis, the specific types of cancer, and whether other cancers occur within the family.

Nora’s Breast Cancer Risk Assessment

Nora’s reported lifetime risk of 23.8% would place her above the threshold commonly used to identify women who may benefit from enhanced breast cancer surveillance, if that estimate is generated by an appropriate validated risk model. However, risk calculators can produce different estimates depending on the model and the information entered.

Because Nora has a notable family history, genetic counseling should be considered. BRCA1 testing may be appropriate if her family history meets established testing criteria, but testing should ideally be guided by a healthcare professional or genetic counselor rather than automatically assumed from the information provided.

Recommendations for Nora

Nora should discuss her family history with a healthcare provider and consider genetic counseling. If genetic testing identifies a pathogenic variant associated with hereditary breast cancer, her screening and risk-reduction plan can be tailored accordingly.

Lifestyle factors are also important. Maintaining a healthy weight, engaging in regular physical activity, avoiding tobacco, and limiting alcohol can contribute to overall cancer prevention. Nutrition should emphasize a balanced dietary pattern rather than relying on a single food or supplement as a cancer-prevention strategy.

Nora should also review her reproductive and hormonal history with her healthcare provider. Factors such as age at first full-term pregnancy, age at menarche, menopausal status, and hormonal contraceptive use can contribute to breast cancer risk assessment, but they should be considered as part of the complete clinical picture.

Key Breast Cancer Risk Factors Identified in These Cases

Across the four patient profiles, several established breast cancer risk factors appear repeatedly. These include:

• Having a close relative with breast cancer, particularly when diagnosed at a young age.
• Carrying an inherited pathogenic variant such as BRCA1 or BRCA2.
• Increasing age.
• Certain reproductive and hormonal factors.
• Use of some forms of menopausal hormone therapy.
• Alcohol consumption.
• Physical inactivity and excess body weight, particularly after menopause.
• A personal history of certain cancers or high-risk breast lesions.

Not every risk factor carries the same level of significance, and having one or more risk factors does not mean that a person will develop breast cancer. Individual risk assessment is therefore more useful than evaluating a single factor in isolation.

Importance of Individualized Breast Cancer Screening

Breast cancer screening should be based on age, personal medical history, family history, genetic risk, and the individual’s estimated lifetime risk. Standard mammography is an important screening tool, while women with sufficiently high risk may be candidates for additional screening, such as breast MRI.

Screening intervals should come from evidence-based guidelines and an individual’s healthcare provider. Very frequent screening, such as mammography every 40 days, is not a standard recommendation for breast cancer screening.

Conclusion

Mary, Paula, June, and Nora each demonstrate how different personal and family characteristics can affect breast cancer risk. Mary’s mother’s early breast cancer diagnosis and Paula’s sister’s reported BRCA1 mutation are particularly important hereditary-risk considerations. June’s family history and hormonal history warrant continued risk assessment, while Nora’s reported elevated lifetime risk may justify discussion of enhanced screening and genetic counseling.

The most appropriate approach is individualized risk assessment rather than relying on a single risk factor or a fixed screening schedule. Healthcare professionals can combine family history, genetic information, reproductive history, lifestyle factors, and validated risk models to determine appropriate screening and preventive strategies.

References

Aurin, J., Thorlacius, H., & Butt, S. T. (2020). Age at first childbirth and breast cancer survival: A prospective cohort study. BMC Research Notes, 13, 1–7. https://doi.org/10.1186/s13104-019-4864-1

Baldini, E., Lauro, A., Tripodi, D., Pironi, D., Amabile, M. I., Ferent, I. C., Lori, E., Gagliardi, F., Bellini, M. I., Forte, F., Pacini, P., Cantisani, V., D’Andrea, V., Sorrenti, S., & Ulisse, S. (2022). Thyroid diseases and breast cancer. Journal of Personalized Medicine, 12(2), 156. https://doi.org/10.3390/jpm12020156

Bardaweel, S. K., Akour, A. A., Al-Muhaissen, S., AlSalamat, H. A., & Ammar, K. (2019). Oral contraceptive and breast cancer: Do benefits outweigh the risks? A case-control study from Jordan. BMC Women’s Health, 19, 4. https://doi.org/10.1186/s12905-019-0770-x

Godinho-Mota, J. C. M., Gonçalves, L. V., Mota, J. F., Soares, L. R., Schincaglia, R. M., Martins, K. A., & Freitas-Junior, R. (2019). Sedentary behavior and alcohol consumption increase breast cancer risk regardless of menopausal status: A case-control study. Nutrients, 11(8), 1842. https://doi.org/10.3390/nu11081871

Lee, K., Kruper, L., Dieli-Conwright, C. M., & Mortimer, J. E. (2019). The impact of obesity on breast cancer diagnosis and treatment. Current Oncology Reports, 21(5), 41. https://doi.org/10.1007/s11912-019-0787-1

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287

BIO FPX 1000 Assessment 6 Patient Case Study Profiles – Cancer Causes

Manyonda, I., Talaulikar, V., Pirhadi, R., Ward, J., Banerjee, D., & Onwude, J. (2022). Could perimenopausal estrogen prevent breast cancer? Exploring the differential effects of estrogen-only versus combined hormone replacement therapy. Journal of Clinical Medicine Research, 14(1), 1–7. https://doi.org/10.14740/jocmr4646

Nañez, A., Stram, D. A., Powell, C. B., & Garcia, C. (2022). Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer. Gynecologic Oncology Reports, 39, 100899. https://doi.org/10.1016/j.gore.2021.100899

Sahin, I., Bilir, B., Ali, S., Sahin, K., & Kucuk, O. (2019). Soy isoflavones in integrative oncology: Increased efficacy and decreased toxicity of cancer therapy. Integrative Cancer Therapies, 18, 153473541983531. https://doi.org/10.1177/1534735419835310

Shahida, S., Rehman, S., Ilyas, N., Khan, M. I., Hameed, U., Hafeez, M., Iqbal, S., Elboughdiri, N., Ghernaout, D., Salih, A. A., & Matouq, M. (2021). Determination of blood calcium and lead concentrations in osteoporotic and osteopenic patients in Pakistan. ACS Omega, 6(42), 28373–28378. https://doi.org/10.1021/acsomega.1c04565

Suri, S., Kumar, V., Kumar, S., Goyal, A., Tanwar, B., Kaur, J., & Kaur, J. (2019). DASH dietary pattern: A treatment for non-communicable diseases. Current Hypertension Reviews, 15. https://doi.org/10.2174/1573402115666191007144608